Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

IgG4-TREAT Systematic study of IgG4-autoimmune diseases to develop new treatment strategies

Coordinator
Medizinische Universitaet Wien, Austria
Runs
1 September 2023 to 31 August 2027
Status
Running
EU funding
€2.6m
Total cost
—
Partners
20 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119457

What the project is doing

In the project's own words, from its summary on CORDIS.

IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affectingmany different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive to current treatments. IgG4-AIDhave commonalities indicating a shared underlying immunopathogenesis that make a joint approach to identify new therapeutictargets and test new treatment strategies feasible and necessary.

We hypothesize that genetic risk factors and a dysregulatedimmune response may lead to an increased susceptibility to produce antibodies targeting self-proteins. These are of a specialsubclass called IgG4, which are usually harmless but can cause disease in these patients by interfering with normal functions in thebody. We are the first consortium that aims to study IgG4-AID comparatively, including pathogenic IgG4, and the cells, molecules andmechanisms involved in IgG4 autoantibody production, using an explorative multi-omics approaches in combination with state-ofthe-art cell and molecular biology methodology.

We will establish a new humanized mouse model of IgG4-AID for the developmentand testing of a novel immune-apheresis based therapy aimed as immediate relief therapy for all IgG4-AID patients. Our innovativetraining program combines university-based and multidisciplinary research-based training with state-of the art web-based trainingand in-person trainings by the academic and non-academic sector. We aim to foster a new generation of experts in IgG4-AID that are1) are highly employable both in the academic and industry sectors and qualified for innovative multidisciplinary translationalresearch with a focus on biomedical product development and 2) equipped with the skillsets for digitalization, awareness for genderequality and diversity and competent in sustainable research and innovation approaches to address current and future challenges,such as climate change, social inequalities and pandemics.

Topics

Who is involved

OrganisationCityCountryRole
Medizinische Universitaet WienWienAustriaCoordinator
Masarykova univerzitaBrnoCzechiaAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Christian-Albrechts-Universitaet Zu KielKielGermanyAssociatedpartner
GenerateKielGermanyAssociatedpartner
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceAssociatedpartner
Hellenic Pasteur InstituteAthensGreeceAssociatedpartner
Tzartos - Diagnosis & Research in Neuroimmunology Medical Limited Liability CompanyAthensGreeceParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainAssociatedpartner
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Sorbonne UniversiteParisFranceAssociatedpartner
Azienda Ospedaliero Universitaria PisanaPisaItalyAssociatedpartner
Fondazione Istituto Neurologico Nazionale Casimiro MondinoPaviaItalyAssociatedpartner
Universita Di PisaPisaItalyAssociatedpartner
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Universiteit Van AmsterdamAmsterdamNetherlandsAssociatedpartner
Istanbul UniversitesiIstanbulTürkiyeParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI